EGFR and lung cancer: In the study by M. Pfeifer et al., genome-wide loss (CRISPRn) and gain (CRISPRa) of function were used to identify genes and pathways contributing to EGFR-dependent mechanisms of resistance to osimertinib in EGFR-mutated lung cancer [54].